Alex Sparreboom, PhD
Leadership Title: Lucius A. Wing Chair of Cancer Research and Therapy
Academic Title: Professor
Research Program: Translational Therapeutics
About Me
More info forI am the Lucius A Wing Chair of Cancer Research and Therapy, and a member of the Translational Therapeutics Program at the OSUCCC – James, where I seek to improve the long-term outcome of patients by modulating the therapeutic window of widely used chemotherapeutics. My work studies the contribution of solute carriers to chemotherapy-induced toxicity profiles, identifies chemical inhibitors of critical transporters and translates the findings to clinical trials.
I am the co-holder of several U.S., European and world patents. One group of patents was secured for predicting responsiveness of a tumor to therapeutic treatment by correlating the CYP1B1 or ABCB1 genotype status of a tumor cell to the therapeutic treatment. Another group of patents was obtained for predicting a prognostic outcome of a subject suffering from androgen independent prostate cancer by determining the SLCO1B3 genotype status and correlating that to overall survival.
Among my recent research is the development of transport modulators to be used in conjunction with platinum-based drugs and tyrosine-kinase inhibitors, with an emphasis on developing innovative pre-clinical model systems.
I have co-authored more than 50 articles appearing in such well-respected publications as Clinical Cancer Research, Journal of Clinical Investigation and Proceedings of the National Academy of Sciences USA. Additionally, he has shared his research in over 100 presentations to various organizations, including the American Association for Cancer Research, the American Society for Clinical Pharmacology and Therapeutics and the American Society of Clinical Oncology.
Academic Office & Contact Information
More info forAcademic Office:
Riffe Building R0514
496 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-685-6014Email:
sparreboom.1@osu.eduPublications
More info forAugust 29, 2024Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen.
Drabison T, Boeckman M, Yang Y, Huang KM, de Bruijn P, Nepal MR, Silvaroli JA, Chowdhury AT, Eisenmann ED, Cheng X, Pabla N, Mathijssen RHJ, Baker SD, Hu S, Sparreboom A, Talebi Z
Cancer Res Commun
August 19, 2024Proton Pump Inhibitors May Cause a Decline in eGFR by Inhibiting Organic Cation Transporter 2-Dependent Creatinine Secretion.
Pabla NS, Sparreboom A
J Am Soc Nephrol
June 14, 2024Pharmacokinetic assessment of low dose decitabine in combination therapies: Development and validation of a sensitive UHPLC-MS/MS method for murine plasma analysis.
Anabtawi N, Drabison T, Jin Y, Eisenmann ED, Sparreboom A, Govindarajan R, Baker SD, Ahmed E
J Chromatogr B Biomed Sci Appl
April 2, 2024Quantification of the aromatase inhibitor letrozole and its carbinol metabolite in mouse plasma by UHPLC-MS/MS.
Taheri H, Jin Y, Ahmed E, Hu P, Li Y, Sparreboom A, Hu S
J Chromatogr B Biomed Sci Appl
March 16, 2024Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
Buck SAJ, Talebi Z, Drabison T, Jin Y, Gibson AA, Hu P, de Bruijn P, de Ridder CMA, Stuurman D, Hu S, van Weerden WM, Koolen SLW, de Wit R, Sparreboom A, Mathijssen RHJ, Eisenmann ED
Int J Cancer
January 24, 2024Membrane transporters in drug development and as determinants of precision medicine.
Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sjöstedt N, Aleksunes L, Chu X, Evers R, Hafey MJ, Lai Y, Matsson P, Riselli A, Shen H, Sparreboom A, Varma MVS, Yang J, Yang X, Yee SW, Zamek-Gliszczynski MJ, Zhang L, Giacomini KM
Nat Rev Drug Discov
December 8, 2023Vincristine Disposition and Neurotoxicity are Unchanged in Humanized CYP3A5 Mice.
Li Y, Kazuki Y, Drabison T, Kobayashi K, Fujita KI, Xu Y, Jin Y, Ahmed E, Li J, Eisenmann ED, Baker SD, Cavaletti G, Sparreboom A, Hu S
Drug Metab Dispos
November 1, 2023Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method.
Talebi Z, Garrison DA, Eisenmann ED, Parmar K, Shapiro GI, Rudek MA, Sparreboom A, Jin Y
Heliyon
October 4, 2023Unique Cabozantinib Dosing Considerations in People Living with HIV and Cancer.
Eisenmann ED, Sparreboom A
Clin Cancer Res
June 1, 2023Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice.
Persaud AK, Bernier MC, Massey MA, Agrawal S, Kaur T, Nayak D, Xie Z, Weadick B, Raj R, Hill K, Abbott N, Joshi A, Anabtawi N, Bryant C, Somogyi A, Cruz-Monserrate Z, Amari F, Coppola V, Sparreboom A, Baker SD, Unadkat JD, Phelps MA, Govindarajan R
Nat Commun
April 7, 2023Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MS.
Talebi Z, Jin Y, Baker SD, Addison D, Sparreboom A
J Chromatogr B Biomed Sci Appl
November 1, 2022Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
Nepal MR, Taheri H, Li Y, Talebi Z, Uddin ME, Jin Y, DiGiacomo DF, Gibson AA, Lustberg MB, Hu S, Sparreboom A
Cancer Res Commun
October 12, 2022Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B.
Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED
Molecules
September 13, 2022A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities.
Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S
Pharmaceutics
August 27, 2022Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method.
Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S
J Chromatogr B Biomed Sci Appl
May 11, 2022Transporters and Toxicity: Insights from the International Transporter Consortium Workshop 4.
Hafey MJ, Aleksunes LM, Bridges CC, Brouwer KR, Chien HC, Leslie EM, Hu S, Li Y, Shen J, Sparreboom A, Sprowl J, Tweedie D, Lai Y
Clin Pharmacol Ther
March 23, 2022Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination.
Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim JG, Sparreboom A, Savona MR, Mims AS, Baker SD
Pharmaceutics
January 1, 2022Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer.
Talebi Z, Sparreboom A, Colace SI
Methods Mol Biol
January 1, 2022Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.
Talebi Z, Sparreboom A, Colace SI
Methods Mol Biol
November 25, 2021In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors.
Uddin ME, Talebi Z, Chen S, Jin Y, Gibson AA, Noonan AM, Cheng X, Hu S, Sparreboom A
Pharmaceutics
October 6, 2021Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia.
Zavorka Thomas ME, Jeon JY, Talebi Z, Buelow DR, Silvaroli J, Campbell MJ, Sparreboom A, Pabla N, Baker SD
Blood Adv
September 21, 2021Precision Dosing of Targeted Therapies is Ready for Prime Time.
Groenland SL, Verheijen RB, Joerger M, Mathijssen RHJ, Sparreboom A, Beijnen JH, Beumer JH, Steeghs N, Huitema ADR
Clin Cancer Res
September 14, 2021Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.
Bai Y, Kim JY, Bisunke B, Jayne LA, Silvaroli JA, Balzer MS, Gandhi M, Huang KM, Sander V, Prosek J, Cianciolo RE, Baker SD, Sparreboom A, Jhaveri KD, Susztak K, Bajwa A, Pabla NS
Kidney Int
September 13, 2021Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-positive AML.
Zavorka Thomas ME, Lu X, Talebi Z, Jeon JY, Buelow DR, Gibson AA, Uddin ME, Brinton LT, Nguyen J, Collins M, Lodi A, Sweeney SR, Campbell MJ, Sweet DH, Sparreboom A, Lapalombella R, Tiziani S, Baker SD
Molecular Cancer Therapeutics
September 10, 2021Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation.
Li Y, Talebi Z, Chen X, Sparreboom A, Hu S
Molecules
July 30, 2021Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma.
Garrison DA, Jin Y, Uddin ME, Sparreboom A, Baker SD
J Chromatogr B Biomed Sci Appl
July 8, 2021Contribution of Membrane Transporters to Chemotherapy-Induced Cardiotoxicity.
Uddin ME, Moseley A, Hu S, Sparreboom A
Basic Clin Pharmacol Toxicol
June 21, 2021Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates.
Marie S, Hernández-Lozano I, Breuil L, Truillet C, Hu S, Sparreboom A, Tournier N, Langer O
Pharmaceutics
June 12, 2021Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.
Eisenmann ED, Talebi Z, Sparreboom A, Baker SD
Basic Clin Pharmacol Toxicol
May 3, 2021Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.
Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, Hecht DP, Klute KA, Morrison VA, Pini TM, Rosner GL, Runowicz CD, Shayne M, Sparreboom A, Turner S, Zarwan C, Lyman GH
J Clin Oncol
March 4, 2021Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation.
Hayden E, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA
Clin Cancer Res
February 21, 2021Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies.
Jin Y, Li Y, Uddin ME, Sparreboom A, Hu S
J Chromatogr B Analyt Technol Biomed Life Sci
February 2, 2021Targeting OCT3 attenuates doxorubicin-induced cardiac injury.
Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A
Proc Natl Acad Sci U S A
January 1, 2021Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1.
Uddin ME, Garrison DA, Kim K, Jin Y, Eisenmann ED, Huang KM, Gibson AA, Hu Z, Sparreboom A, Hu S
Front Pharmacol
September 29, 2020Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Mout L, Moll JM, Chen M, de Morrée ES, de Ridder CMA, Gibson A, Stuurman D, Aghai A, Erkens-Schulze S, Mathijssen RHJ, Sparreboom A, de Wit R, Lolkema MP, van Weerden WM
Br J Cancer
September 9, 2020DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD
Clin Transl Sci
September 9, 2020Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors.
Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD
Pharmaceutics
August 20, 2020Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.
Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S
Pharmaceutics
August 7, 2020Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.
Anderson JT, Huang KM, Lustberg MB, Sparreboom A, Hu S
Rev Physiol Biochem Pharmacol
June 2, 2020Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice.
Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson A, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg M, Cavaletti G, Pabla N, Hu S, Sparreboom A
J Clin Invest
May 20, 2020Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies.
Eisenmann ED, Jin Y, Weber RH, Sparreboom A, Baker SD
J Chromatogr B Analyt Technol Biomed Life Sci
April 22, 2020Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors.
Atrafi F, van Eerden RAG, van Hylckama Vlieg MAM, Oomen-de Hoop E, de Bruijn P, Lolkema M, Moelker A, Rijcken C, Hanssen R, Sparreboom A, Eskens FALM, Mathijssen RH, Koolen SL
Clin Cancer Res
April 21, 2020A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury.
Kim JY, Bai Y, Jayne LA, Hector RD, Persaud AK, Ong SS, Rojesh S, Raj R, Feng MJHH, Chung S, Cianciolo RE, Christman JW, Campbell MJ, Gardner DS, Baker SD, Sparreboom A, Govindarajan R, Singh H, Chen T, Poi M, Susztak K, Cobb SR, Pabla NS
Nat Commun
April 10, 2020Role of SLC transporters in toxicity induced by anticancer drugs.
Huang KM, Uddin ME, DiGiacomo D, Lustberg MB, Hu S, Sparreboom A
Expert Opin Drug Metab Toxicol